These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27494891)

  • 1. Analysis of the chemotherapeutic effects of a propadiene compound on malignant ovarian cancer cells.
    Li S; Yang L; Wang J; Liang F; Chang B; Gu H; Wang H; Yang G; Chen Y
    Oncotarget; 2016 Aug; 7(35):57145-57159. PubMed ID: 27494891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
    Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
    Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
    Nonaka M; Itamochi H; Kawaguchi W; Kudoh A; Sato S; Uegaki K; Naniwa J; Sato S; Shimada M; Oishi T; Terakawa N; Kigawa J; Harada T
    Int J Gynecol Cancer; 2012 Jul; 22(6):922-9. PubMed ID: 22672985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
    Liu Y; Chen X; Luo Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary.
    Itamochi H; Nishimura M; Oumi N; Kato M; Oishi T; Shimada M; Sato S; Naniwa J; Sato S; Kudoh A; Kigawa J; Harada T
    Int J Gynecol Cancer; 2014 Jan; 24(1):61-9. PubMed ID: 24362713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer.
    Huang S; Wang D; Zhang S; Huang X; Wang D; Ijaz M; Shi Y
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):685-696. PubMed ID: 28779263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ; Chen BL; Xin XY
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
    Shen W; Liang B; Yin J; Li X; Cheng J
    Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
    Yang YI; Kim JH; Lee KT; Choi JH
    Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
    Chen XX; Xie FF; Zhu XJ; Lin F; Pan SS; Gong LH; Qiu JG; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Shi Z; Yan XJ
    Oncotarget; 2015 Jun; 6(17):14926-39. PubMed ID: 25962959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy.
    Zhang X; Qi Z; Yin H; Yang G
    Theranostics; 2019; 9(4):1096-1114. PubMed ID: 30867818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
    Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
    Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the cytotoxicity of the Bithionol-paclitaxel combination in a panel of human ovarian cancer cell lines.
    Ayyagari VN; Diaz-Sylvester PL; Hsieh TJ; Brard L
    PLoS One; 2017; 12(9):e0185111. PubMed ID: 28931042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin combined with cisplatin reduces anticancer activity via ATM/CHK2-dependent upregulation of Rad51 pathway in ovarian cancer.
    Zhang J; Zhou P; Wu T; Zhang L; Kang J; Liao J; Jiang D; Hu Z; Han Z; Zhou B
    Neoplasia; 2024 Nov; 57():101037. PubMed ID: 39142065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
    Asselin E; Mills GB; Tsang BK
    Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.